1826 ET - Cracker Barrel hasn't seen any effects of growing adoption of GLP-1 weight-loss drugs on its sales, Chief Executive Officer Julie Masino says on an analyst call. "We have been actively monitoring GLP-1s for over a year now," she says. "We have not seen any measurable impact at Cracker Barrel to date." She adds that the company offers portion flexibility, substantial protein offerings, and lighter options on its menu. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
June 09, 2026 18:26 ET (22:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.